A Scalable Design for Proximity-Inducing Molecules

This paper introduces GRIPs (GRoup-transfer chimeras for Inducing Proximity), a scalable and versatile platform that utilizes abundant effector inhibitors and a diverse toolbox of group-transfer handles to create chimeric molecules for editing post-translational modifications, thereby overcoming the scalability limitations of traditional chimeras and enabling new therapeutic functionalities.

The Gist

The Big Idea: The "Molecular Glue" Problem

Imagine your body is a massive, bustling city. In this city, there are Workers (enzymes) who add or remove specific tags (Post-Translational Modifications, or PTMs) on buildings (proteins). These tags tell the buildings what to do: "Open the doors," "Lock the windows," or "Demolish this wall."

Sometimes, the city gets into trouble because the wrong tags are on the wrong buildings, or the right tags are missing. This causes diseases like cancer or neurodegenerative disorders.

For a long time, scientists tried to fix this by building "Molecular Glue" (chimeras). This glue has two sticky ends:

1. One end grabs a specific Worker (the enzyme).
2. The other end grabs a specific Building (the protein causing trouble).

The Problem: To make this glue work, the end that grabs the Worker had to be a very special, rare type of "activator" that tells the Worker to start working. But finding these rare activators is like trying to find a specific key in a haystack of millions. Most Workers don't even have a place for this key. Because of this, scientists could only fix a tiny fraction of the city's problems.

The Solution: GRIPs (The "Delivery Drone")

The authors of this paper invented a new system called GRIPs (GRoup-transfer chimeras for Inducing Proximity).

Instead of needing a rare "activator key," GRIPs use common inhibitors (drugs that usually stop a Worker from working). Think of it like this:

• Old Way: You need a rare, magical key to unlock a door and tell the worker to start.
• GRIPs Way: You use a common "Do Not Enter" sign (an inhibitor) that the worker is already familiar with. But, you attach a special delivery drone to this sign.

How it works:

1. The "Do Not Enter" sign (the drug) grabs onto the Worker.
2. Once it's attached, the "delivery drone" (a chemical handle) snaps a piece of the sign onto the Worker's hand.
3. This action forces the Worker to grab the Building (the target protein) that is holding the other end of the drone.
4. The Worker is now right next to the Building and immediately starts adding or removing the necessary tags.
5. Once the job is done, the "Do Not Enter" sign falls off, leaving the Worker free to do more jobs.

Why is this a Big Deal?

1. It's Scalable (The "Lego" Effect)
Because there are thousands of common "Do Not Enter" signs (inhibitors) already available in medicine, scientists can now build GRIPs for almost any Worker they want. They don't need to hunt for rare keys anymore. They just need to find a common drug that fits the Worker and attach the drone.

• Analogy: Instead of hand-carving a unique key for every door, they realized they could use a standard screwdriver (the common drug) and just swap out the drill bit (the handle) to fix anything.

2. It Works on "Hidden" Workers
The paper shows they can fix problems involving three different types of tags:

• Phosphorylation: Adding a phosphate tag (like turning a light switch on/off).
• O-GlcNAc: Adding a sugar tag (like putting a sticker on a file).
• Tyrosine Phosphorylation: A specific type of switch.

They successfully built GRIPs for enzymes that were previously impossible to target.

Real-World Superpowers

The paper demonstrates that GRIPs can do things old drugs couldn't:

• Stopping the "Rebound" Effect:

  • Scenario: Imagine you take a painkiller that stops a signal. When you stop taking it, the pain comes back worse than before (rebound).
  • GRIP Fix: The GRIP doesn't just block the signal; it actively cleans up the "primed" signal so that when the drug wears off, there is no explosion of activity. It prevents the "rebound" crash.

• The "Event-Driven" Drug:

  • Scenario: Old drugs sit on a target like a parking meter, waiting to be paid (occupancy). If the target moves, the drug falls off.
  • GRIP Fix: GRIPs are like a delivery truck that drops off a package and leaves. The effect happens because the package was delivered, not because the truck is still parked there. This makes the drug more potent and longer-lasting.

• Turning On the "Growth Factor" Switch:

  • Scenario: In biomanufacturing (making medicines in cells), scientists usually add expensive, unstable proteins (like EGF) to tell cells to grow.
  • GRIP Fix: They used a GRIP to trick the cells into thinking EGF was there, causing them to grow. This is cheaper and more stable than using the real protein.

• The "Goldilocks" Trap for Cancer:

  • Scenario: Cancer cells are like Goldilocks; they need signaling to be "just right." Too little, they die; too much, they die.
  • GRIP Fix: The GRIPs can over-activate a specific signal in cancer cells (those with a specific mutation) to push them past the "just right" point and kill them, while leaving healthy cells alone.

The Toolkit

To make this work, the authors built a massive toolbox:

• 42 different "Drone Handles": These are the chemical connectors that snap onto the enzymes. They come in different sizes and strengths to fit different enzymes.
• 5,000+ Compatible Drugs: They mapped out thousands of existing drugs that can be turned into GRIPs.

Summary

Think of the old way of fixing cellular problems as trying to find a specific, rare key for every single lock in a city. It was slow, expensive, and often impossible.

GRIPs are like a universal delivery service. They use the millions of keys we already have (common drugs), attach a smart drone to them, and force the city's workers to fix the specific problems we care about. It's a scalable, versatile, and powerful new way to edit the "software" of our cells.

Technical Summary

1. The Problem

Proximity-inducing chimeras (e.g., PROTACs) are transformative tools that recruit effector enzymes (writers/erasers) to a protein of interest (POI) to add or remove post-translational modifications (PTMs). However, current designs face a critical scalability bottleneck:

• Scarcity of Non-Inhibitory Binders: Traditional chimeras require binders that recruit the effector without inhibiting its catalytic activity (often activators or non-inhibitory binders). Such binders are extremely rare (e.g., reported for only ~3 of 538 human kinases) and difficult to discover.
• Limited Scope: This scarcity restricts chimera development to <1% of all writer/eraser enzymes, preventing the editing of PTMs across diverse biological sequences.
• Off-Target Effects: Existing strategies using kinase activators often induce large-scale off-target phosphorylation due to global enzyme activation.

2. Methodology: The GRIPs Platform

The authors developed GRoup-transfer chimeras for Inducing Proximity (GRIPs), a scalable platform that repurposes abundant, high-quality inhibitors of writers/erasers to induce proximity.

• Core Mechanism: Instead of using a non-inhibitory binder, GRIPs utilize a standard inhibitor connected to a POI binder via a group-transfer handle.
  • The inhibitor binds to the effector enzyme.
  • The handle reacts with a proximal nucleophilic residue (Cysteine or Lysine) on the effector.
  • This reaction covalently transfers the POI binder (or a linker attached to it) onto the effector, physically recruiting the effector to the POI.
  • Crucially, the inhibitor is released (or "washed out") after the transfer, uncoupling the pharmacological inhibition of the effector from the proximity induction.
• Bioinformatic Mining: The team mined the Protein Data Bank (PDB) and chemoproteomic datasets to identify >5,000 inhibitor-enzyme pairs where the inhibitor binding pocket is within 15 Å of a reactive Cysteine or Lysine.
• Chemical Toolbox Development:
  • Cysteine Handles: Developed 42 tunable group-transfer handles with varying reactivity and length to react with cysteines near inhibitor binding pockets.
  • Lysine Handles: Overcame limitations of existing lysine-reactive handles (e.g., hydrolytic instability of NASA fragments) by developing a new class of SuFA (N-sulfonyl-N-trifluoromethyl ethanamide) handles. These offer tunable reactivity, improved stability, and reduced steric bulk.
• Target PTMs: The platform was validated for three distinct PTMs:
  1. Dephosphorylation (Ser/Thr and Tyr) using the phosphatase SHP2.
  2. De-O-GlcNAcylation using OGA (O-GlcNAcase).
  3. O-GlcNAcylation using OGT (O-GlcNAc transferase).

3. Key Contributions

• Scalability: Demonstrated the creation of 6 distinct GRIP classes covering 16 effector-POI pairs (4 fully endogenous), utilizing diverse inhibitor chemotypes (covalent, non-covalent, allosteric, active-site).
• First-in-Class Recruitment: Reported the first small-molecule chimeras capable of recruiting endogenous writers/erasers for O-GlcNAc and Tyrosine phosphorylation without requiring overexpression or chemogenetic tagging.
• Chemical Tool Development: Provided a library of 42 tunable handles for Cys/Lys and validated >5,000 potential inhibitor-residue pairs, significantly expanding the chemical space for proximity induction.
• Mechanistic Innovation: Established a "group-transfer" mechanism that allows the effector to be recruited without permanently inhibiting it, and allows the inhibitor to be released post-reaction.

4. Key Results

A. Platform Validation & Specificity

• Global Proteomics: Confirmed high specificity of group-transfer. For example, an SHP2-targeting probe labeled SHP2 with >64-fold enrichment over background with minimal off-targets.
• Endogenous Recruitment: Successfully recruited endogenous SHP2 to dephosphorylate STAT3-FKBP and Tau-FKBP, blocking downstream JAK-STAT signaling and reducing pathological tau phosphorylation.

B. Therapeutic Applications (Fully Endogenous Systems)

1. Preventing Rebound Signaling (JAK2):
   • Problem: JAK inhibitors (e.g., Baricitinib) stabilize a kinase conformation that prevents phosphatase access, leading to hyperphosphorylation and dangerous "rebound signaling" upon drug withdrawal.
   • Solution: A SHP2-JAK2 GRIP recruited SHP2 to dephosphorylate JAK2.
   • Outcome: Prevented rebound signaling in myeloproliferative neoplasm models and showed potent cytotoxicity, overcoming the limitations of occupancy-based inhibitors.
2. Potent STAT3 Inhibition:
   • A SHP2-STAT3 GRIP (using the STAT3 inhibitor SI-109) achieved dephosphorylation of endogenous STAT3 at concentrations 4x lower than the occupancy-based inhibitor, demonstrating superior potency via an "event-driven" mechanism.
3. Persistent EGFR Inhibition:
   • SHP2-EGFR GRIPs (based on Gefitinib) induced more sustained dephosphorylation of EGFR and downstream effectors (AKT, ERK) compared to standard inhibitors or previous dual-inhibitor approaches.
4. Synthetic Lethality via Overactivation (TOVER):
   • An EGFR-activating GRIP (using Osimertinib) dimerized endogenous EGFR, mimicking EGF.
   • Outcome: Induced selective cell death in KRAS-mutant cancer cells (via therapeutic overactivation of oncogenic signaling) while sparing wild-type cells, a phenomenon not achievable with Osimertinib alone.

C. Biological Control & Phase Separation

• Condensate Formation: GRIPs recruiting AKT to Liprin-α3 induced dose- and time-controlled phase separation (condensate formation).
• Reduced Off-Targets: Unlike conventional chimeras using kinase activators (which caused global phosphoproteome dysregulation), the AKT-GRIP induced specific condensates with minimal global phosphoproteomic perturbation.

D. Biomanufacturing Application

• EGFR-activating GRIPs served as proteolytically stable, low-cost alternatives to EGF for stimulating cell proliferation in biomanufacturing (HEK293T and CHO cells), increasing protein production yields by ~75%.

5. Significance

• Paradigm Shift: GRIPs shift the paradigm from "finding rare non-inhibitory binders" to "repurposing abundant high-quality inhibitors," making proximity induction scalable across the entire proteome.
• Therapeutic Potential: The platform offers a solution to common drug limitations, such as rebound signaling and resistance, by converting inhibitors into proximity inducers.
• Research Utility: Provides a versatile toolbox for studying PTM crosstalk, phase separation, and signaling dynamics with high temporal and spatial control.
• Future Outlook: While in vivo efficacy and safety remain to be determined, the modularity and reliance on existing drug scaffolds position GRIPs as a powerful next-generation therapeutic modality for basic research and clinical development.